Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Chiesi Group has presented data at two international congresses on the role of its extrafine formulation ICS/LABA/LAMA vs LABA/LAMA in the treatment of COPD patients

firstwordpharmaMay 30, 2018

Tag: Chiesi Group , international congresses , LABA/LAMA

PharmaSources Customer Service